Clinical Observation of Inhaled Tiotropium in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease_West China Medical Journal

Authors：

HE Dachuan , DONG Qiong , WANG Bo , PU Qing , GAO Han , XIE Yong

Department of Respiratory Medicine, Central Hospital of Nanchong (The Sencond Hospital of North Sichuan Medical College), Nanchong, Sichuan 637000, P. R. China;

Corresponding author：

Keywords：

噻托溴铵; 慢性阻塞性肺疾病; 急性加重期; 临床疗效

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　观察噻托溴铵治疗慢性阻塞性肺疾病急性加重期（AECOPD）临床疗效与安全性。方法　选取 2010 年 1 月－2011年12月入院的69例AECOPD 患者随机分为试验组（A组，n=36）和对照组（B组，n=33），A组在B组常规治疗的基础上吸入噻托溴铵。治疗起始及结束分别观察两组肺功能指标、慢性阻塞性肺疾病评估测试（CAT）评分、血气分析、6分钟步行距离、住院时间及药物不良反应。结果　两组均显示出一定的临床效果，A组治疗后肺功能指标、CAT评分、血气分析、6分钟步行距离均优于B组，差异均具有统计学意义（P＜0.05）。A组住院时间短于B组（P＜0.05），且无严重不良反应。结论　 AECOPD患者在常规治疗同时吸入噻托溴铵，疗效显著且临床安全性较高。

Citation： HE Dachuan,DONG Qiong,WANG Bo,PU Qing,GAO Han,XIE Yong. Clinical Observation of Inhaled Tiotropium in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. West China Medical Journal, 2012, 27(12): 1837-1839. doi: Copy

1.	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2007年修订版)[J]. 中华结核和呼吸杂志，2007, 30(1)：8-17.
2.	Donaldson GC, Wedzicha JA. COPD exacerbations.1: Epidemiology[J]. Thorax，2006，61(2): 164-168.
3.	包宇旺，罗建雄，史洪辉，等. 重度、极重度COPD急性加重期合并多器官功能障碍226例临床研究[J]. 华西医学, 2009, 24(10): 2588-2590.
4.	Fromer L， Barnes T， Garvey C，et al. Innovations to achieve excellence in COPD diagnosis and treatment in primary care[J]. Postgrad Med，2010，122(5): 150-164.
5.	Han MK, Martinez FJ. Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease[J]. Proc Am Thorac Soc, 2011, 8(4) : 356-362.
6.	钟南山. 慢性阻塞性肺疾病在中国[J]. 中国实用内科杂志，2011, 31(5)：321-322.
7.	O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium onlung hyperinflation dyspnoea and exercise tolerance in COPD[J]. Eur Respir J, 2004, 23(6): 832-840.
8.	Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease[J]. Clin Ther, 2005, 27(4): 377-392.
9.	Tashkin DP，Celli B, Senn S, et al. A 4 - year trial of tiotropium in chronic obstructive pulmonary disease[J]. N Engl J Med, 2008, 359(15) : 1543-1554 .
10.	van Noord JA, Smeets JJ, Custers FL, et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease[J]. Eur Respir J, 2002, 19(4): 639-644.
11.	Vogelmeier C, Hederer B, Glaab T, et al. Totropium versus Salmeterol for the prevention of exacerbations of COPD[J]. N Engl J Med, 2011, 364(12): 1093-1103.
12.	Pieper MP, Chaudhary NI, Park JE. Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide[J]. Life Sci, 2007, 80(24-25): 2270-2273.
13.	梁剑, 张溪林, 郑云, 等. 噻托溴铵改善COPD患者急性加重和气流受限的疗效研究[J]. 临床医学工程, 2011, 18(8): 1186-1189.
14.	史冬瑶, 孙力军. 联合应用噻托溴铵与沙美特罗/氟替卡松治疗慢性阻塞性肺疾病的疗效观察[J]. 中国医药指南, 2012, 10(3): 159-160.
15.	Santus P, Di Marco F. Safety and pharmacological profile of tiotropium bromide[J]. Expert Opin Drug Saf, 2009, 8(3): 387-395.

1. 　中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2007年修订版)[J]. 中华结核和呼吸杂志，2007, 30(1)：8-17.
2. 　Donaldson GC, Wedzicha JA. COPD exacerbations.1: Epidemiology[J]. Thorax，2006，61(2): 164-168.
3. 　包宇旺，罗建雄，史洪辉，等. 重度、极重度COPD急性加重期合并多器官功能障碍226例临床研究[J]. 华西医学, 2009, 24(10): 2588-2590.
4. 　Fromer L， Barnes T， Garvey C，et al. Innovations to achieve excellence in COPD diagnosis and treatment in primary care[J]. Postgrad Med，2010，122(5): 150-164.
5. 　Han MK, Martinez FJ. Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease[J]. Proc Am Thorac Soc, 2011, 8(4) : 356-362.
6. 　钟南山. 慢性阻塞性肺疾病在中国[J]. 中国实用内科杂志，2011, 31(5)：321-322.
7. 　O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium onlung hyperinflation dyspnoea and exercise tolerance in COPD[J]. Eur Respir J, 2004, 23(6): 832-840.
8. 　Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease[J]. Clin Ther, 2005, 27(4): 377-392.
9. 　Tashkin DP，Celli B, Senn S, et al. A 4 - year trial of tiotropium in chronic obstructive pulmonary disease[J]. N Engl J Med, 2008, 359(15) : 1543-1554 .
10. 　van Noord JA, Smeets JJ, Custers FL, et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease[J]. Eur Respir J, 2002, 19(4): 639-644.
11. 　Vogelmeier C, Hederer B, Glaab T, et al. Totropium versus Salmeterol for the prevention of exacerbations of COPD[J]. N Engl J Med, 2011, 364(12): 1093-1103.
12. 　Pieper MP, Chaudhary NI, Park JE. Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide[J]. Life Sci, 2007, 80(24-25): 2270-2273.
13. 　梁剑, 张溪林, 郑云, 等. 噻托溴铵改善COPD患者急性加重和气流受限的疗效研究[J]. 临床医学工程, 2011, 18(8): 1186-1189.
14. 　史冬瑶, 孙力军. 联合应用噻托溴铵与沙美特罗/氟替卡松治疗慢性阻塞性肺疾病的疗效观察[J]. 中国医药指南, 2012, 10(3): 159-160.
15. 　Santus P, Di Marco F. Safety and pharmacological profile of tiotropium bromide[J]. Expert Opin Drug Saf, 2009, 8(3): 387-395.

West China Medical Journal

Clinical Observation of Inhaled Tiotropium in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Abstract Full text Figures/Tables Video References Cited by

Format

Content